Eight cholesterol-lowering lactic acid bacteria(LAB 1 through 8)isolated from pickles and yogurt were evaluated for probiotic potential based on their tolerance to low pH and bile salt and antagonistic activity agains...Eight cholesterol-lowering lactic acid bacteria(LAB 1 through 8)isolated from pickles and yogurt were evaluated for probiotic potential based on their tolerance to low pH and bile salt and antagonistic activity against Staphylococcus aureusand Escherichia coli.Strain LAB 4 had excellent tolerance to low pH and bile salt and all 8 LAB strains had antagonisticactivity against Staphylococcus aureus and Escherichia coli.Moreover,strain LAB4 had synergic cholesterol-lowering effect with 0.0125%licorice root extract,0.025%Chinese wolfberry extract or 0.025%milkvetch root extract.展开更多
慢性病患者的长期管理是基层医疗的核心任务之一,患者的规律随访(TR)与疾病预后密切相关。近期Annals of Family Medicine刊发了一篇文章《Teamwork among Primary Care Staff to Achieve Regular Follow-Up of Chronic Patients》,该...慢性病患者的长期管理是基层医疗的核心任务之一,患者的规律随访(TR)与疾病预后密切相关。近期Annals of Family Medicine刊发了一篇文章《Teamwork among Primary Care Staff to Achieve Regular Follow-Up of Chronic Patients》,该文章指出慢性病患者的TR面临多重挑战,既往研究多聚焦于患者个体因素,而忽视了医疗团队动态对随访率的潜在影响。展开更多
OBJECTIVE The emergence of evolving variants of Coronavirus disease 2019(COVID-19)has fostered the need for change of newer and adaptive treatments for these infections.During the COVID-19 pandemic and persists,tradit...OBJECTIVE The emergence of evolving variants of Coronavirus disease 2019(COVID-19)has fostered the need for change of newer and adaptive treatments for these infections.During the COVID-19 pandemic and persists,traditional Chinese medicine(TCM)herbs exhibit significant bioactivity and therapeutic effect.This study is aimed to evaluate the efficacy of four TCM preparations on 28-day mortality risk of patients and changes of the laboratory indicators.METHODS The retrospective cohort study included patients with COVID-19 who were admitted to the Jiangsu Province Hospital of Chinese Medicine from December 15,2022 to January 15,2023,and those died within 48 hours of admission or cannot be tracked for outcomes were excluded.The primary outcome was survival status in 28 days(death or survival)starting from the day of admission.The second outcomes were laboratory indicators,including absolute lymphocyte count,lactate dehydrogenase,creatinine,and blood urea nitrogen.Binary logistic regressions were used to estimate the effect of TCM preparations on the primary and secondary outcomes in main analysis.Meanwhile,heterogeneity and robustness of results from main analysis were assessed by subgroup analyses and multiple sensitivity analyses.RESULTS 1816 eligible patients were included in analysis dataset,including 573 patients received standard care(control group)and 1243 patients received TCM preparations(hospital preparation group).The 28-day mortality rate of hospital preparation group was lower than that of control group(4.75%vs.14.83%),and the difference was statistically significant(χ^(2)=54.666,P<0.001).The risk of 28-day mortality was 0.535 times lower in the hospital preparation group as compared with the control group(OR=0.46,95%CI:0.305-0.708,P<0.001)showed by multivariable binary logistic regressions.Subgroup analyses showed that taking TCM preparations reduced the 28-day mortality risk.Sensitivity analyses demonstrated that the results of the main analysis for primary outcomes were robust.For secondary outcomes,the risk of abnormal absolute lymphocyte counts at discharge in the hospital preparation group decreased by 0.284 times(OR=0.703,95%CI:0.515-0.961,P=0.027).CONCLUSION Compared with standard of care,taking four hospital preparations including Kanggan Heji,Feining Heji,Qishen Gubiao Keli,and Qianghuo Qushi Qingwen Heji decreased risk of 28-day mortality among hospitalized COVID-19 patients.TCM therapy achieves adequate therapeutic effects in COVID-19.展开更多
通过药物治疗使耳鸣减轻或消失是医患双方的共同期待,因而寻找有效治疗耳鸣的药物一直是耳鸣研究的重点之一。国内外学者在耳鸣的药物治疗方面进行着不懈的探索,所得结果不尽相同,尚未能形成药物治疗方面的共识[1~3];而且,至今没有任何...通过药物治疗使耳鸣减轻或消失是医患双方的共同期待,因而寻找有效治疗耳鸣的药物一直是耳鸣研究的重点之一。国内外学者在耳鸣的药物治疗方面进行着不懈的探索,所得结果不尽相同,尚未能形成药物治疗方面的共识[1~3];而且,至今没有任何药物被FDA（food and drug administration）或者EMEA（european medicines agency）标识为＂耳鸣治疗用药，医生始终在为没有疗效确切的药物可用于治疗耳鸣而苦恼。展开更多
2014年10月美国《Otolaryngology-Head and Neck Surgery》杂志增刊发表了《耳鸣临床应用指南(Clinical Practice Guideline:Tinnitus)》。该《指南》由David E.Tunkel等23位学者共同制定,是首部用于评估和治疗慢性耳鸣的指南,旨在为从...2014年10月美国《Otolaryngology-Head and Neck Surgery》杂志增刊发表了《耳鸣临床应用指南(Clinical Practice Guideline:Tinnitus)》。该《指南》由David E.Tunkel等23位学者共同制定,是首部用于评估和治疗慢性耳鸣的指南,旨在为从事耳鸣研究与治疗的专业人员提供基于循证医学证据的建议。《指南》涉及的患者群体是患有持续失代偿性的原发性耳鸣患者(18岁及以上)。本文试结合我国目前耳鸣诊治现状将该《指南》作一解读。展开更多
文摘Eight cholesterol-lowering lactic acid bacteria(LAB 1 through 8)isolated from pickles and yogurt were evaluated for probiotic potential based on their tolerance to low pH and bile salt and antagonistic activity against Staphylococcus aureusand Escherichia coli.Strain LAB 4 had excellent tolerance to low pH and bile salt and all 8 LAB strains had antagonisticactivity against Staphylococcus aureus and Escherichia coli.Moreover,strain LAB4 had synergic cholesterol-lowering effect with 0.0125%licorice root extract,0.025%Chinese wolfberry extract or 0.025%milkvetch root extract.
文摘慢性病患者的长期管理是基层医疗的核心任务之一,患者的规律随访(TR)与疾病预后密切相关。近期Annals of Family Medicine刊发了一篇文章《Teamwork among Primary Care Staff to Achieve Regular Follow-Up of Chronic Patients》,该文章指出慢性病患者的TR面临多重挑战,既往研究多聚焦于患者个体因素,而忽视了医疗团队动态对随访率的潜在影响。
文摘OBJECTIVE The emergence of evolving variants of Coronavirus disease 2019(COVID-19)has fostered the need for change of newer and adaptive treatments for these infections.During the COVID-19 pandemic and persists,traditional Chinese medicine(TCM)herbs exhibit significant bioactivity and therapeutic effect.This study is aimed to evaluate the efficacy of four TCM preparations on 28-day mortality risk of patients and changes of the laboratory indicators.METHODS The retrospective cohort study included patients with COVID-19 who were admitted to the Jiangsu Province Hospital of Chinese Medicine from December 15,2022 to January 15,2023,and those died within 48 hours of admission or cannot be tracked for outcomes were excluded.The primary outcome was survival status in 28 days(death or survival)starting from the day of admission.The second outcomes were laboratory indicators,including absolute lymphocyte count,lactate dehydrogenase,creatinine,and blood urea nitrogen.Binary logistic regressions were used to estimate the effect of TCM preparations on the primary and secondary outcomes in main analysis.Meanwhile,heterogeneity and robustness of results from main analysis were assessed by subgroup analyses and multiple sensitivity analyses.RESULTS 1816 eligible patients were included in analysis dataset,including 573 patients received standard care(control group)and 1243 patients received TCM preparations(hospital preparation group).The 28-day mortality rate of hospital preparation group was lower than that of control group(4.75%vs.14.83%),and the difference was statistically significant(χ^(2)=54.666,P<0.001).The risk of 28-day mortality was 0.535 times lower in the hospital preparation group as compared with the control group(OR=0.46,95%CI:0.305-0.708,P<0.001)showed by multivariable binary logistic regressions.Subgroup analyses showed that taking TCM preparations reduced the 28-day mortality risk.Sensitivity analyses demonstrated that the results of the main analysis for primary outcomes were robust.For secondary outcomes,the risk of abnormal absolute lymphocyte counts at discharge in the hospital preparation group decreased by 0.284 times(OR=0.703,95%CI:0.515-0.961,P=0.027).CONCLUSION Compared with standard of care,taking four hospital preparations including Kanggan Heji,Feining Heji,Qishen Gubiao Keli,and Qianghuo Qushi Qingwen Heji decreased risk of 28-day mortality among hospitalized COVID-19 patients.TCM therapy achieves adequate therapeutic effects in COVID-19.
文摘通过药物治疗使耳鸣减轻或消失是医患双方的共同期待,因而寻找有效治疗耳鸣的药物一直是耳鸣研究的重点之一。国内外学者在耳鸣的药物治疗方面进行着不懈的探索,所得结果不尽相同,尚未能形成药物治疗方面的共识[1~3];而且,至今没有任何药物被FDA（food and drug administration）或者EMEA（european medicines agency）标识为＂耳鸣治疗用药，医生始终在为没有疗效确切的药物可用于治疗耳鸣而苦恼。
文摘2014年10月美国《Otolaryngology-Head and Neck Surgery》杂志增刊发表了《耳鸣临床应用指南(Clinical Practice Guideline:Tinnitus)》。该《指南》由David E.Tunkel等23位学者共同制定,是首部用于评估和治疗慢性耳鸣的指南,旨在为从事耳鸣研究与治疗的专业人员提供基于循证医学证据的建议。《指南》涉及的患者群体是患有持续失代偿性的原发性耳鸣患者(18岁及以上)。本文试结合我国目前耳鸣诊治现状将该《指南》作一解读。
